Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H38N4O4 |
Molecular Weight | 398.5401 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN(CCN(CCCC)C(=O)N1CCOCC1)C(=O)N2CCOCC2
InChI
InChIKey=HZTMGWSBSDLALI-UHFFFAOYSA-N
InChI=1S/C20H38N4O4/c1-3-5-7-21(19(25)23-11-15-27-16-12-23)9-10-22(8-6-4-2)20(26)24-13-17-28-18-14-24/h3-18H2,1-2H3
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/43915 and
https://www.drugs.com/international/dimorpholamine.html
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/43915 and
https://www.drugs.com/international/dimorpholamine.html
Dimorpholamine is reported as an ingredient of Theraptique in Japan. Dimorpholamine stimulates the respiratory and circulatory centers to increase the respiratory volume and blood pressure. It is indicated for the respiratory and circulatory insufficiency due to shock, hypnotic intoxication. drowning, pneumonia, and high fever.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0003009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/43915 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Theraptique Approved UseIndications: Respiratory and circulatory insufficiency due to shock, hypnotic intoxication. drowning, pneumonia, and high fever. |
Sample Use Guides
30-60 mg (1-2 ampoules) via the intramuscular route. If necessary, the same dose may be given repeatedly unless the daily dose exceeds 200 mg (6.5 ampoules).
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/43915
Low concentrations (about 2 x 10(-5) g/ml) of dimorpholamine potentiate the twitch contraction of frog sartorius muscle. In relatively high concentrations of 10(-4)--10(-3) g/ml, however, the potentiation was followed by depression.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3091
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
DTXSID5057628
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
SUB13613MIG
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
100000079211
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
8YL4JT0L91
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
m699
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
204-328-7
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104294
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
3732
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
119-48-2
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
C65410
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY | |||
|
C100074
Created by
admin on Fri Dec 15 16:21:59 GMT 2023 , Edited by admin on Fri Dec 15 16:21:59 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD